Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Micetinoftalmina is an ophthalmic ointment containing chloramphenicol (10 mg/g), developed and marketed by the Portuguese pharmaceutical company DÁVI. Chloramphenicol is a broad-spectrum small molecule antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome, primarily exerting a bacteriostatic effect. It is indicated for the topical treatment of external eye infections and associated structures, including conjunctivitis, keratitis, blepharitis, and corneal ulcers, caused by susceptible microorganisms. The product is an approved, marketed medication in Portugal and is often used at night in combination with the eye drop formulation of the same name.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Micetinoftalmina ointment.